Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy

For decades, treatment of chronic lymphocytic leukemia (CLL) has been based on chemotherapy. This changed when the first CD20 antibody rituximab was introduced. Since 2008, the combination of chemotherapy and CD20 antibodies has become the standard of care for most patients, and a significant fracti...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Sawaf, Othman, Fischer, Kirsten, Engelke, Anja, Pflug, Natali, Hallek, Michael, Goede, Valentin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279834/
https://www.ncbi.nlm.nih.gov/pubmed/28182141
http://dx.doi.org/10.2147/DDDT.S104869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5279834/
https://www.ncbi.nlm.nih.gov/pubmed/28182141
http://dx.doi.org/10.2147/DDDT.S104869

Ejemplares similares